A breakdown of the oral obesity drug race: Novo's pill is a peptide that leans on the SNAC absorption enhancer, while Lilly's orforglipron is a small molecule with no meal timing rules.
Recap by typeshit. Full story at note.
A sponsored-style explainer that walks through semaglutide versus tirzepatide and the post-shortage compounding limits, while featuring telehealth company Mochi Health.
ABC News' chief medical correspondent walks through the latest Novo Nordisk GLP-1 medication and what sets it apart from drugs already on the market.
18:51
A doctor walks through four of the most talked about weight loss drugs in one overview, covering the big names people ask about most.
Investseekers shares notes on the upcoming French rollout of the Wegovy pill and where Novo Nordisk might launch it next in Europe.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
17:44
NP on a GLP draws on both her clinical work and her own time on the medication to cover what she thinks people starting a GLP-1 should know.
Loading…